MacroGenics Management
Management criteria checks 4/4
MacroGenics' CEO is Scott Koenig, appointed in Sep 2001, has a tenure of 22.67 years. total yearly compensation is $3.71M, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 2.08% of the company’s shares, worth $19.19M. The average tenure of the management team and the board of directors is 7.3 years and 6.9 years respectively.
Key information
Scott Koenig
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 19.0% |
| CEO tenure | 22.7yrs |
| CEO ownership | 2.1% |
| Management average tenure | 7.3yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28
MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21MacroGenics: Revisiting Our Pipeline And Investment Analysis
Aug 10MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be
Aug 03MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology
Jun 16MacroGenics, Inc. 2021 Q1 - Results - Earnings Call Presentation
Apr 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$705k | -US$9m |
| Sep 30 2023 | n/a | n/a | US$50m |
| Jun 30 2023 | n/a | n/a | US$7m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$5m | US$673k | -US$120m |
| Sep 30 2022 | n/a | n/a | -US$191m |
| Jun 30 2022 | n/a | n/a | -US$219m |
| Mar 31 2022 | n/a | n/a | -US$217m |
| Dec 31 2021 | US$5m | US$651k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$146m |
| Jun 30 2021 | n/a | n/a | -US$129m |
| Mar 31 2021 | n/a | n/a | -US$136m |
| Dec 31 2020 | US$3m | US$656k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$158m |
| Jun 30 2020 | n/a | n/a | -US$167m |
| Mar 31 2020 | n/a | n/a | -US$152m |
| Dec 31 2019 | US$5m | US$590k | -US$152m |
| Sep 30 2019 | n/a | n/a | -US$166m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$5m | US$599k | -US$171m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$34m |
| Mar 31 2018 | n/a | n/a | -US$32m |
| Dec 31 2017 | US$3m | US$554k | -US$20m |
Compensation vs Market: Scott's total compensation ($USD3.71M) is about average for companies of similar size in the US market ($USD3.42M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
CEO
Scott Koenig (71 yo)
22.7yrs
Tenure
US$3,705,825
Compensation
Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 22.7yrs | US$3.71m | 2.08% $ 19.2m | |
| Senior VP | 16yrs | US$1.58m | 0.27% $ 2.5m | |
| Senior VP of Clinical Development & Chief Medical Officer | 3.8yrs | US$1.75m | 0.016% $ 144.8k | |
| Chief Operating Officer | 2.3yrs | US$1.92m | 0.062% $ 574.9k | |
| Senior Vice President of Technical Operations | 1.5yrs | US$1.88m | 0.013% $ 122.9k | |
| Senior VP of Research & Chief Scientific Officer | 7.7yrs | US$2.29m | 0.16% $ 1.5m | |
| Senior VP | 6.9yrs | no data | no data | |
| VP, Controller & Treasurer | 20.6yrs | no data | 0.0099% $ 91.8k |
7.3yrs
Average Tenure
60.5yo
Average Age
Experienced Management: MGNX's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 22.7yrs | US$3.71m | 2.08% $ 19.2m | |
| Independent Director | 10.7yrs | US$160.75k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$152.00k | 0% $ 0 | |
| Independent Director | 19.6yrs | US$147.63k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$318.32k | 0% $ 0 | |
| Independent Chairman of the Board | 2yrs | US$180.13k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$335.41k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$167.63k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$167.21k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$135.75k | 0% $ 0 |
6.9yrs
Average Tenure
65yo
Average Age
Experienced Board: MGNX's board of directors are considered experienced (6.9 years average tenure).